Welcome to our dedicated page for POSITRON SEC filings (Ticker: POSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Positron Corporation filings document the medical technology company's Exchange Act reporting status, capital structure, auditor matters, and material corporate events. The records identify POSC common stock on OTC Markets and describe share issuances, including a subscription agreement for common stock sold in an unregistered offering under Regulation S.
Recent Form 8-K disclosures also cover changes in the company's independent registered public accounting firm and the engagement of a new auditor for annual and interim financial statement work. Positron's regulatory disclosures are centered on its PET and PET-CT molecular imaging business, governance, accounting oversight, and equity financing activity.
POSITRON CORP (POSC) entered into a Line of Credit Agreement with affiliated investor George Ortiz on August 13, 2026. The facility provides a maximum aggregate principal of $2,000,000, with the company able to draw at its discretion, subject to a $500,000 per-calendar-quarter cap and a $50,000 minimum draw. Amounts repaid may be reborrowed within these limits.
The outstanding principal bears interest at a fixed 12% per annum, payable quarterly in arrears. For the first 12 months (the “Interest-Only Period”), only interest is due; during the following 12 months, both principal and interest are payable. All advances are due August 13, 2028, with optional prepayment at any time without penalty. Events of default include non-payment, covenant breaches, insolvency, and material adverse events, after which default interest of 18% per annum (or the legal maximum) may apply.
As additional consideration, Positron issued Ortiz warrants for 300,000 common shares at an exercise price of $1.50 per share, expiring December 31, 2030. If the company defaults on interest or principal payments when due, the warrant exercise price automatically reprices to $1.00 per share.
Positron Corporation reported a small revenue base driven entirely by service income, with $222,822 in revenue for the six months ended June 30, 2026 compared with $239,452 a year earlier. The company generated no equipment sale revenue because control of PET/PET‑CT systems has not yet transferred to customers.
The business recorded a six‑month net loss of $2,199,169, narrower than the prior‑year loss of $2,703,123, but cash used in operations was substantial at $1,838,293. Cash and cash equivalents fell to $357,173 from $2,520,466 at December 31, 2025, and total assets declined to $1,728,405.
Liabilities of $2,389,252, including a $875,000 related‑party note and a $563,000 convertible advance payable, exceeded assets, resulting in a stockholders’ deficit of $(660,847) and an accumulated deficit of $147,136,248. Management states that recurring losses, limited cash, and expected insufficient operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Subsequent to quarter‑end, a related party provided a $2,000,000 unsecured line of credit and received 300,000 equity warrants; the same party exercised 250,000 existing warrants for $250,000 of expected proceeds, providing additional but conditional liquidity support.
Positron Corporation reports another quarterly loss and flags serious liquidity concerns. For the three months ended March 31, 2026, the company generated only $111,000 of maintenance contract revenue and recorded a net loss of $1,377,769, or $0.04 per share, slightly better than the $1,512,382 loss a year earlier.
Cash and cash equivalents fell to $1,406,756 from $2,520,466 at year-end, as operating activities used $788,710 of cash and loan repayments used another $325,000. Total assets were $2,792,078 against total liabilities of $2,631,525, leaving stockholders’ equity of just $160,553, down sharply from $1,443,822 at December 31, 2025.
The company discloses that it does not expect to generate sufficient revenue and positive operating cash flow to meet current obligations and may need new debt or equity financing. Management states that these conditions raise substantial doubt about Positron’s ability to continue as a going concern within 12 months. Shares issued and outstanding were 32,849,451 at March 31, 2026 and 32,846,326 issued as of May 15, 2026.
Positron Corporation filed its annual report detailing continued losses and going concern risk. The medical imaging company reported 2025 revenue of $461,452, down from $587,500 in 2024, while net loss widened to $10,603,392 and accumulated deficit reached $144,937,079.
The report states there is substantial doubt about Positron’s ability to continue as a going concern, as operations are not expected to generate sufficient cash to meet obligations without additional financing. At December 31, 2025, cash was $2,520,466 with current liabilities of $2,402,141 and working capital of $937,045.
To fund operations, Positron raised $10,000,000 from common stock sales in 2025 but also repurchased 4,000,000 shares for $2,500,000. It granted 5,150,000 fully vested stock options at $1.48 per share to management and highlighted plans to commercialize its Affinity PET-CT system while relying heavily on future capital-raising efforts.
Positron Corporation disclosed that on December 23, 2025 it entered into a Subscription Agreement with a single investor to sell 1,333,333 shares of its common stock for an aggregate purchase price of $2,000,000. The transaction was completed without the use of a placement agent or finder, meaning the company dealt directly with the investor.
The shares were issued in a private transaction not registered under the Securities Act of 1933, relying on the Regulation S exemption. This issuance represents new equity capital for Positron and results in additional common shares outstanding. The company also filed the Subscription Agreement and a related press release as exhibits.
Positron Corporation reports a change in its independent auditor. Freed Maxick P.C. resigned as the company’s independent registered public accounting firm effective October 31, 2025. On December 10, 2025, the company appointed Salberg & Company, P.A. as its new independent registered public accounting firm.
Salberg has been engaged to audit Positron Corporation’s financial statements for the year ended December 31, 2025 and to review interim financial statements for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026. The company states that during the two most recent fiscal years and through December 10, 2025, it did not consult with Salberg on the application of accounting principles, the type of audit opinion that might be issued, or on any matter involving a “disagreement” or “reportable event” as defined in SEC rules.